Optimizing Control of Fever & Pain in Clinical Settings – An in-Vitro Investigation of the Dissolution and Disintegration Characteristics of Optizorb Technology in Acetaminophen Tablets versus Other Marketed Products

Reduced inter-patient variability and consistent therapeutic effects are prerequisites in formulating drugs for reliable fever and pain control. The bioavailability of paracetamol is variable, leading to variable onset and duration of action. Optizorb technology incorporates a patented technology aimed at rapid dissolution and absorption of active ingredients, and improving the bioavailability of paracetamol. This study compared the dissolution of various paracetamol formulations versus the patented 'Optizorb' technology-based paracetamol tablets (Crocin Advance 650), determined the rate of disintegration in aqueous media and resultant changes in pH, and analyzed the residue profile. The dissolution test utilized media closely resembling the gastrointestinal environment (0.1N HCl, pH 5.8 phosphate buffered medium and pH 6.8 phosphate buffered medium). The disintegration test was performed using 1,000 mL of water as disintegration media. In 0.1N HCL, Crocin 650 mg tablets released 61% of the drug at 1-minute time interval, and 94% at the 3-minute time interval. The disintegration time for Crocin 650 was 48 seconds in water. Crocin 650 exhibited complete disintegration and dissolution in water, leaving no residues in the medium. Crocin Advance 650 with Optizorb technology ensures rapid, consistent drug release and may provide clinically relevant reduction in inter- and intra-patient variability and improved bioavailability.